4//SEC Filing
SALIX PHARMACEUTICALS LTD 4
Accession 0001209191-14-002646
CIK 0001009356operating
Filed
Jan 8, 7:00 PM ET
Accepted
Jan 9, 4:49 PM ET
Size
10.3 KB
Accession
0001209191-14-002646
Insider Transaction Report
Form 4
KEANE WILLIAM P
Director
Transactions
- Sale
Common Stock
2014-01-07$88.31/sh−22,500$1,986,975→ 35,240 total - Exercise/Conversion
Option to Buy Common Stock
2014-01-07−22,500→ 0 totalExercise: $18.87Exp: 2014-06-17→ Common Stock (22,500 underlying) - Exercise/Conversion
Common Stock
2014-01-07$18.87/sh+22,500$424,649→ 57,740 total
Holdings
- 15,000
Option to Buy Common Stock
Exercise: $17.63Exp: 2015-06-09→ Common Stock (15,000 underlying)
Footnotes (3)
- [F1]The exercise and sale were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2013.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.93 to $88.88, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- [F3]Options are 100% vested.
Documents
Issuer
SALIX PHARMACEUTICALS LTD
CIK 0001009356
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001009356
Filing Metadata
- Form type
- 4
- Filed
- Jan 8, 7:00 PM ET
- Accepted
- Jan 9, 4:49 PM ET
- Size
- 10.3 KB